{"disease":{"id":"mpnst","name":"mpnst"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT05677594","title":"Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT07298083","title":"DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04811196","title":"A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06849986","title":"IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05985161","title":"A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06735820","title":"Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"AeRang Kim","has_results":false},{"nct_id":"NCT05253131","title":"Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":41,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT00004853","title":"Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05642455","title":"SPEARHEAD-3 Pediatric Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"USWM CT, LLC","has_results":false},{"nct_id":"NCT02211768","title":"Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04091295","title":"BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Aveni Foundation","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}